Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Phosphoserine enriched dense collagen bioink
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.ORCID iD: 0000-0002-3957-9190
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Cell Biology.
Uppsala University, Disciplinary Domain of Science and Technology, Chemistry, Department of Chemistry - Ångström, Macromolecular Chemistry.ORCID iD: 0000-0002-0932-0161
Department of Animal Bioscience, Swedish University of Agricultural Sciences, Uppsala, Sweden .
Show others and affiliations
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Phosphoserine (pSER) is a phosphorylated amino acid commonly found in non-collagenous bone proteins and is implicated in the regulation of calcium phosphate (CaP) mineral formation and interfacial interactions in native bone. Here, we soaked 3D printed collagen scaffolds, with or without prior mineralisation, in pSER and investigated the early cellular response by assessing pre-osteoblast viability through ATP content measurements at day 3. The scaffolds were further evaluated in a rat uni-cortical femoral defect model and analysed by micro-computed tomography (µCT) and histology after 6 weeks. In parallel, standard 2D cultures of MC3T3-E1 cells and rat mesenchymal stromal cells (rMSCs) were exposed to pSER, nanohydroxyapatite (nHA), or a combination of both to assess dose-dependent effects in the absence of a scaffold environment. Using a dose-dependent screening approach, we identified 0.05% pSER on mineralised collagen scaffolds as the concentration that resulted in the highest cell viability, whereas higher concentrations were cytotoxic. This concentration was further evaluated in a time-dependent setup over 7 days and again showed increased cell viability compared to untreated collagen scaffolds. Similar trends were observed in vivo where CaP-containing groups demonstrated a higher bone volume fraction than CaP-free collagen groups, and pSER-associated effects were detectable but less pronounced. Overall, the results indicate that collagen scaffolds combining pSER and CaP lead to a dose-dependent enhanced pre-osteoblast viability in vitro. Future work will explore how these pSER-modified collagen bioinks influence bone cell differentiation and aim to elucidate the mechanisms through which pSER supports bone regeneration in vivo. 

National Category
Biomaterials Science
Research subject
Medical Science
Identifiers
URN: urn:nbn:se:uu:diva-582588OAI: oai:DiVA.org:uu-582588DiVA, id: diva2:2047060
Available from: 2026-03-18 Created: 2026-03-18 Last updated: 2026-03-18
In thesis
1. Applications of Additive Manufacturing for Advancing Cell Models from 2D to 3D
Open this publication in new window or tab >>Applications of Additive Manufacturing for Advancing Cell Models from 2D to 3D
2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Two-dimensional (2D) cell culture systems are widely used in preclinical research due to their ease of handling and standardisation, but do not adequately reflect key aspects of the complex three-dimensional (3D) physiological microenvironment. This limits the predictive value of in vitro studies for both drug development and biomaterials research. The overall aim of this thesis was to explore how additive manufacturing supports the transition from 2D to more advanced 3D cell culture models.

In Study I, CombiCTx, a cell culture device for combinatorial anti-cancer drug testing, was developed. The system enables the formation of overlapping drug gradients through diffusion in a hydrogel matrix, and an assay and imaging analysis protocol was established. Using breast cancer cells, it was demonstrated that the assay can identify synergistic drug effects and that, for the drugs tested, these effects were spatially confined to specific regions of the assay space, highlighting the importance of diffusion processes not captured in standard 2D assays.

In Study II, an open source extrusion-based bioprinter based on the E3D motion system was established to increase accessibility to bioprinting technologies. The system supports multimaterial printing and FRESH bioprinting. Collagen scaffolds and cell-laden laminin-containing constructs were printed, and high cell viability was maintained, demonstrating the suitability of the platform for generating 3D cell culture environments.

Studies III and IV focused on biomaterials for bone regeneration. In Study III, the biosafety of a phosphoserine (pSER)-modified calcium phosphate bone adhesive was evaluated. Both in vitro and in vivo results indicated good biocompatibility, with no evidence of adverse immune reactions or ectopic bone formation.

In Study IV, 3D bioprinted collagen-silica hybrid scaffolds modified with pSER were investigated. In vitro experiments showed a dose-dependent effect of pSER in combination with calcium phosphate on cell viability. In vivo, mineralised scaffolds promoted bone formation, suggesting an osteogenic potential of these materials.

In conclusion, the studies presented in this thesis demonstrate that additive manufacturing can be used to develop more advanced in vitro models and to investigate biomaterials in controlled 3D environments. These approaches will contribute to improving the translation of preclinical findings into clinical applications.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2026. p. 73
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine, ISSN 1651-6206 ; 2248
Keywords
3D printing, additive manufacturing, 3D bioprinting, in vitro, biomaterials, combinatorial drug screening, bioink
National Category
Medical Biotechnology
Research subject
Medical Science
Identifiers
urn:nbn:se:uu:diva-582589 (URN)978-91-513-2779-2 (ISBN)
Public defence
2026-05-08, A1:107a, Biomedical Center (BMC), Husargatan 3, Uppsala, 09:15 (English)
Opponent
Supervisors
Available from: 2026-04-16 Created: 2026-03-18 Last updated: 2026-04-16

Open Access in DiVA

No full text in DiVA

Authority records

Stelzl, ChristinaNorein, NoreinSehic, EdinaCarlsson, ElinProcter, PhilipHilborn, JönsHulsart Billström, Gry

Search in DiVA

By author/editor
Stelzl, ChristinaNorein, NoreinSehic, EdinaCarlsson, ElinProcter, PhilipHilborn, JönsHulsart Billström, Gry
By organisation
Department of Medical Cell BiologyMacromolecular ChemistryApplied Material ScienceBiomedical EngineeringScience for Life Laboratory, SciLifeLab
Biomaterials Science

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 47 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf